Merck Plans to Move Global Headquarters within New Jersey - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Merck Plans to Move Global Headquarters within New Jersey


ePT--the Electronic Newsletter of Pharmaceutical Technology

Merck & Co. has announced plans to relocate the company’s global headquarters within the state of New Jersey (NJ), with the transition expected to begin in 2014 and be completed by mid-2015, according to an Oct. 9, 2012, press release. The company will close its current headquarters building in Whitehouse Station, NJ, where it has been since 1992, and move the headquarters less than 30 miles to the northeast to its existing property in Summit, NJ. The Summit facility currently houses 1800 people in research, manufacturing, animal health, and consumer care operations. About 2000 employees and contractors currently working in Whitehouse Station will move to the Summit location or to other nearby facilities such as those in Branchburg, NJ and Cokesbury, NJ.

The headquarters relocation is part of the company's ongoing program to consolidate its global real estate footprint and lower its annual operating expenses. The Summit location was selected because it is a multiuse site with excess workspace capacity and is near major transportation hubs and urban centers, said the company in the press release.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
25%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here